A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay

Tomoya Tachi, Tetsunari Hase, Yukihiro Okamoto, Noritada Kaji, Takeshi Arima, Hiroyuki Matsumoto, Masashi Kondo, Manabu Tokeshi, Yoshinori Hasegawa, Yoshinobu Baba

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Microchip analysis is a promising method for therapeutic drug monitoring. This led us to evaluate a microchip-based fluorescence polarization immunoassay (FPIA) system for point-of-care testing on patients being treated with theophylline. The sera were collected from 20 patients being treated with theophylline. Fluorescence polarization was measured on the microchip and theophylline concentrations in serum were obtained. Regression analysis of the correlations was done between the results given by the microchip-based FPIA and the conventional cloned enzyme donor immunoassay (CEDIA), and between the results given by the microchip-based FPIA and the conventional particle-enhanced turbidimetric inhibition immunoassay (PETINIA). We successfully carried out a quantitative analysis of theophylline in serum at values near its therapeutic range in 65 s. The results obtained by the microchip-based FPIA correlated well with CEDIA and PETINIA results; the correlation coefficients (R 2) were 0.986 and 0.989, respectively. The FPIA system is a simple and rapid method for point-of-care testing of drugs in serum, and its accuracy is the same as the conventional CEDIA and PETINIA. It is essential to use real samples from patients and to confirm good correlations with conventional methods for a study on the realization of microchip.

Original languageEnglish
Pages (from-to)2301-2305
Number of pages5
JournalAnalytical and Bioanalytical Chemistry
Volume401
Issue number7
DOIs
Publication statusPublished - 01-10-2011

Fingerprint

Fluorescence Polarization Immunoassay
Drug Monitoring
Theophylline
Fluorescence
Clinical Trials
Polarization
Immunoenzyme Techniques
Immunoassay
Monitoring
Pharmaceutical Preparations
Tissue Donors
Serum
Microchip Analytical Procedures
Enzymes
Fluorescence Polarization
Testing
Regression analysis
Regression Analysis
Chemical analysis

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry
  • Biochemistry

Cite this

Tachi, Tomoya ; Hase, Tetsunari ; Okamoto, Yukihiro ; Kaji, Noritada ; Arima, Takeshi ; Matsumoto, Hiroyuki ; Kondo, Masashi ; Tokeshi, Manabu ; Hasegawa, Yoshinori ; Baba, Yoshinobu. / A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay. In: Analytical and Bioanalytical Chemistry. 2011 ; Vol. 401, No. 7. pp. 2301-2305.
@article{9e2e29bd07c94f07947f7d922ddf143b,
title = "A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay",
abstract = "Microchip analysis is a promising method for therapeutic drug monitoring. This led us to evaluate a microchip-based fluorescence polarization immunoassay (FPIA) system for point-of-care testing on patients being treated with theophylline. The sera were collected from 20 patients being treated with theophylline. Fluorescence polarization was measured on the microchip and theophylline concentrations in serum were obtained. Regression analysis of the correlations was done between the results given by the microchip-based FPIA and the conventional cloned enzyme donor immunoassay (CEDIA), and between the results given by the microchip-based FPIA and the conventional particle-enhanced turbidimetric inhibition immunoassay (PETINIA). We successfully carried out a quantitative analysis of theophylline in serum at values near its therapeutic range in 65 s. The results obtained by the microchip-based FPIA correlated well with CEDIA and PETINIA results; the correlation coefficients (R 2) were 0.986 and 0.989, respectively. The FPIA system is a simple and rapid method for point-of-care testing of drugs in serum, and its accuracy is the same as the conventional CEDIA and PETINIA. It is essential to use real samples from patients and to confirm good correlations with conventional methods for a study on the realization of microchip.",
author = "Tomoya Tachi and Tetsunari Hase and Yukihiro Okamoto and Noritada Kaji and Takeshi Arima and Hiroyuki Matsumoto and Masashi Kondo and Manabu Tokeshi and Yoshinori Hasegawa and Yoshinobu Baba",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s00216-011-5304-9",
language = "English",
volume = "401",
pages = "2301--2305",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "0016-1152",
publisher = "Springer Verlag",
number = "7",

}

Tachi, T, Hase, T, Okamoto, Y, Kaji, N, Arima, T, Matsumoto, H, Kondo, M, Tokeshi, M, Hasegawa, Y & Baba, Y 2011, 'A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay', Analytical and Bioanalytical Chemistry, vol. 401, no. 7, pp. 2301-2305. https://doi.org/10.1007/s00216-011-5304-9

A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay. / Tachi, Tomoya; Hase, Tetsunari; Okamoto, Yukihiro; Kaji, Noritada; Arima, Takeshi; Matsumoto, Hiroyuki; Kondo, Masashi; Tokeshi, Manabu; Hasegawa, Yoshinori; Baba, Yoshinobu.

In: Analytical and Bioanalytical Chemistry, Vol. 401, No. 7, 01.10.2011, p. 2301-2305.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A clinical trial for therapeutic drug monitoring using microchip-based fluorescence polarization immunoassay

AU - Tachi, Tomoya

AU - Hase, Tetsunari

AU - Okamoto, Yukihiro

AU - Kaji, Noritada

AU - Arima, Takeshi

AU - Matsumoto, Hiroyuki

AU - Kondo, Masashi

AU - Tokeshi, Manabu

AU - Hasegawa, Yoshinori

AU - Baba, Yoshinobu

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Microchip analysis is a promising method for therapeutic drug monitoring. This led us to evaluate a microchip-based fluorescence polarization immunoassay (FPIA) system for point-of-care testing on patients being treated with theophylline. The sera were collected from 20 patients being treated with theophylline. Fluorescence polarization was measured on the microchip and theophylline concentrations in serum were obtained. Regression analysis of the correlations was done between the results given by the microchip-based FPIA and the conventional cloned enzyme donor immunoassay (CEDIA), and between the results given by the microchip-based FPIA and the conventional particle-enhanced turbidimetric inhibition immunoassay (PETINIA). We successfully carried out a quantitative analysis of theophylline in serum at values near its therapeutic range in 65 s. The results obtained by the microchip-based FPIA correlated well with CEDIA and PETINIA results; the correlation coefficients (R 2) were 0.986 and 0.989, respectively. The FPIA system is a simple and rapid method for point-of-care testing of drugs in serum, and its accuracy is the same as the conventional CEDIA and PETINIA. It is essential to use real samples from patients and to confirm good correlations with conventional methods for a study on the realization of microchip.

AB - Microchip analysis is a promising method for therapeutic drug monitoring. This led us to evaluate a microchip-based fluorescence polarization immunoassay (FPIA) system for point-of-care testing on patients being treated with theophylline. The sera were collected from 20 patients being treated with theophylline. Fluorescence polarization was measured on the microchip and theophylline concentrations in serum were obtained. Regression analysis of the correlations was done between the results given by the microchip-based FPIA and the conventional cloned enzyme donor immunoassay (CEDIA), and between the results given by the microchip-based FPIA and the conventional particle-enhanced turbidimetric inhibition immunoassay (PETINIA). We successfully carried out a quantitative analysis of theophylline in serum at values near its therapeutic range in 65 s. The results obtained by the microchip-based FPIA correlated well with CEDIA and PETINIA results; the correlation coefficients (R 2) were 0.986 and 0.989, respectively. The FPIA system is a simple and rapid method for point-of-care testing of drugs in serum, and its accuracy is the same as the conventional CEDIA and PETINIA. It is essential to use real samples from patients and to confirm good correlations with conventional methods for a study on the realization of microchip.

UR - http://www.scopus.com/inward/record.url?scp=81155159661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155159661&partnerID=8YFLogxK

U2 - 10.1007/s00216-011-5304-9

DO - 10.1007/s00216-011-5304-9

M3 - Article

VL - 401

SP - 2301

EP - 2305

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 0016-1152

IS - 7

ER -